Where generic drug ingredients come from

On Oct. 30, 2019, the head of FDA's drug center told the House Energy and Commerce health subcommittee that China held 230 of the facilities registered to make active ingredients for the US market, or 13 percent. The United States held 510, or 28 percent. She added a caveat that still applies. FDA, her testimony said¹, "cannot determine with any precision the volume of API that China is actually producing" or how much of it reaches American patients.

Seven years on, FDA publishes more location data than it did then, and Congress has given it new reporting powers. The basic gap remains. Federal figures count factories rather than output, and the label on a generic bottle says almost nothing about where the active ingredient was made.

A typical generic tablet comes out of at least two plants. One makes the active pharmaceutical ingredient (API), the chemical that does the medical work. Another blends it with inactive ingredients and presses, fills or packages the finished dose. The two are often owned by different companies in different countries, and the finishing plant may itself be a contract manufacturer.

The 2019 snapshot

FDA's figures came from its August 2019 listings and covered API facilities for all regulated drugs, including prescription, over-the-counter and compounded products:

FDA also looked at 370 drugs on the World Health Organization's essential medicines list that are sold in the US. Of the 1,079 API facilities supplying them, 166 (15 percent) were in China and 221 (21 percent) in the United States, the testimony said¹.

It was candid about the limits. A registered facility may not be making API at all, manufacturers were not then required to report volumes, and FDA could not see which supplier a finished-dose maker was using at a given moment.

Five years of drift toward India and China

FDA's fiscal 2025 Report on the State of Pharmaceutical Quality² took a narrower cut: manufacturing sites for products whose application holder is based in the US, comparing calendar 2020 with 2025.

Finished-dose sites moved the same way. The US share fell from 51.2 percent to 48.0 percent, while China's rose from 2.7 percent to 5.2 percent and India's from 10.5 percent to 12.4 percent. FDA attributed the shift "primarily to the addition of manufacturing sites in China and India," with the number of US and European sites roughly stable, the report said².

Two points stand out. Europe holds the largest share of API sites in that analysis, well ahead of the US. And the US remains the main place where medicines are finished into tablets, capsules and injectables, which is how a product can be finished domestically while its active ingredient comes from abroad. The policy debate over moving more of that work home is covered in our piece on onshoring.

All sites, by country

A year earlier, the fiscal 2024 version of the report³ counted every site in FDA's drug manufacturing catalog, covering API makers, finished-dose plants and other manufacturers but not medical gas producers. At the end of fiscal 2024 the catalog held 4,619 sites, 41 percent of them in the US.

The fiscal 2025 report changed the basis by adding 1,704 medical gas sites, which pushed the total to 5,953 and the US share to 57 percent, FDA noted². The two years are not directly comparable. Inspections of these plants, and the warning letters that follow some of them, are explained in our guide to Form 483s and warning letters.

How a generic is tied to its ingredient supplier

A generic applicant often buys its API from a supplier that has filed a drug master file (DMF) with FDA. A Type II DMF⁴ covers a drug substance, an intermediate or the materials used to make them. The supplier keeps its process confidential and gives the generic company a letter of authorization, which lets FDA review the DMF alongside the generic application.

For DMFs that support generic applications, the supplier pays a one-time fee under the generic drug user fee program. FDA's Federal Register fee notices set it at $102,584 for fiscal 2026⁹ and $109,899 for fiscal 2027¹⁰. FDA then runs a completeness assessment before listing the DMF as available for reference, a screen for missing information that does not replace the full scientific review when an application cites it. FDA's DMF program page⁵ describes the process, and our explainer on GDUFA covers the fee system.

A DMF links an approved generic to specific API sources. Switching to a new supplier generally requires telling FDA and, depending on the change, getting approval first. That is one reason trouble at a single API plant can spread across several finished generics at once. On Oct. 30, 2026, five of the 69 drugs listed as currently in shortage in FDA's shortage data⁸ gave a shortage of an active ingredient as the reason, according to GxRadar's shortage tracker.

What the label tells you

Federal rules require a drug label to name the manufacturer, packer or distributor and its place of business. If the company named is a distributor, its name must be qualified with a phrase such as "Manufactured for," "Distributed by" or "Marketed by," under 21 CFR 201.1⁶. Our guide to reading a prescription label shows where that line appears.

Those rules cover the finished product. Nothing on a typical generic label identifies who made the active ingredient or where. Federal law does not require a drug's country of origin to be disclosed, according to a Senate Special Committee on Aging summary⁷ of the proposed CLEAR LABELS Act. That bill would require the original API maker's name and location to be available on the label or through an electronic portal. It remains a proposal.

FDA's own view has sharpened. Since the CARES Act of March 27, 2020, registered drug establishments must report each year how much of each listed drug they make. Acting under an executive order of May 5, 2025, FDA notified 9,571 registrants on Oct. 14, 2025, that they had not filed their 2024 amount reports, and those still out of compliance by Dec. 31 were added to a public list of noncompliant firms in March 2026, the fiscal 2025 quality report said².

Those reports go to FDA, and patients never see them. For a specific prescription, a pharmacist can usually say which company's product is on the shelf, and the NDC on the bottle identifies the labeler. The API source behind it stays in confidential FDA files.